Premium
A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles
Author(s) -
Niu Yamei,
Komatsu Nobukazu,
Komohara Yoshihiro,
Matsueda Satoko,
Yutani Shigeru,
Ishihara Yuki,
Itou Minoru,
Yamada Akira,
Itoh Kyogo,
Shichijo Shigeki
Publication year - 2009
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.21518
Subject(s) - ctl* , human leukocyte antigen , virology , epitope , peptide , hepatitis c virus , virus , biology , peripheral blood mononuclear cell , hepacivirus , hla a , immunology , microbiology and biotechnology , antigen , cd8 , genetics , in vitro , biochemistry
C35‐44 peptide is a well known HLA‐A2‐restricted CTL epitope originating from hepatitis C virus (HCV) core protein. It was reported that the majority of HCV positive patients had significant levels of serum IgG specific to this peptide. This study addressed whether C35‐44 peptide could induce CTL activity restricted to various HLA class IA alleles or could not. This peptide demonstrated binding activity to HLA‐A*2402, ‐A*2601, ‐A*3101, and ‐A*3303 molecules, but not to HLA‐A*1101 by means of stabilization assay. This peptide also induced CTL activity restricted to each of them, except HLA‐A11 + peripheral blood mononuclear cells from HCV 1b + patients by means of 51 Cr‐release assay. With regard to HLA‐A2 subtypes, this peptide demonstrated binding activity to HLA‐A*0201 and ‐A*0206, but not to ‐A*0207 molecules. Furthermore, this peptide induced CTL activity from both the patients and healthy donors with all the HLA class IA molecules mentioned above by means of interferon‐γ production assay. These results may provide new insights for the development of a novel peptide vaccine against HCV compatible with various HLA class IA types. J. Med. Virol. 81:1232–1240, 2009. © 2009 Wiley‐Liss, Inc.